Pro-inflammatory cytokines, such as interleukin (IL)-1β, have been implicated as underlying pathophysiological mechanisms and potential biomarkers of post-traumatic stress disorder (PTSD). This systematic review examines data regarding IL-1β production/concentration in human and animal studies of PTSD. In accordance with PRISMA guidelines, relevant articles from PubMed were reviewed from inception until July 10, 2017. Nineteen studies were eligible for inclusion. Animal studies demonstrated increased hippocampal IL-1β in rodent models of PTSD. Several immunomodulatory drugs were shown to reduce elevated IL-1β levels and anxiety-like behaviors in animals. Human cross-sectional studies showed contradictory results; serum and plasma IL-1β concentrations in PTSD patients were either elevated or did not differ from control groups. In vitro IL-1β production by stimulated cells demonstrated no difference between PTSD and control participants, although spontaneous in vitro production of IL-1β was increased in the PTSD group. The findings from 2 longitudinal studies were inconsistent. Given the conflicting findings, it is premature to consider IL-1β as a biomarker of PTSD. Anti-inflammatory agents may reduce IL-1β, and be a potential basis for future therapeutic agents in PTSD treatment. More longitudinal research is needed to better understand the role of IL-1β in the development and/or maintenance of PTSD.
Get full access to this article
View all access options for this article.
References
1.
Aga-MizrachiS, Cymerblit-SabbaA, GurmanO, BalanA, ShwamG, DesheR, MillerL, GorodetskyN, HeinrichN, TzezanaO, ZubedatS, GrinsteinD, AvitalA. 2014. Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model. Transl Psychiatry, 4:e447.
2.
American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington, VA: American Psychiatric Publishing.
3.
BersaniFS, WolkowitzOM, LindqvistD, YehudaR, FloryJ, BiererLM, MakotineI, Abu-AmaraD, CoyM, ReusVI, EpelES, MarmarC, MellonSH. 2016. Global arginine bioavailability, a marker of nitric oxide synthetic capacity, is decreased in PTSD and correlated with symptom severity and markers of inflammation. Brain Behav Immun, 52:153–160.
4.
BlakeDD, WeathersFW, NagyLM, KaloupekDG, GusmanFD, CharneyDS, KeaneTM. 1995. The development of a Clinician-Administered PTSD Scale. J Trauma Stress, 8(1):75–90.
5.
BlanchardEB, Jones-AlexanderJ, BuckleyTC, FornerisCA. 1996. Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther, 34(8):669–673.
CapuronL, MillerAH. 2011. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther, 130(2):226–238.
8.
CarmassiC, StrattaP, MassimettiG, BertelloniCA, ConversanoC, CremoneIM, MiccoliM, BaggianiA, RossiA, Dell'OssoL. 2014. New DSM-5 maladaptive symptoms in PTSD: gender differences and correlations with mood spectrum symptoms in a sample of high school students following survival of an earthquake. Ann Gen Psychiatry, 13:28.
9.
ConnorKM, DavidsonJR. 2001. SPRINT: a brief global assessment of post-traumatic stress disorder. Int Clin Psychopharmacol, 16(5):279–284.
10.
Cosen-BinkerLI, BinkerMG, NegriG, TiscorniaO. 2004. Influence of stress in acute pancreatitis and correlation with stress-induced gastric ulcer. Pancreatology, 4(5):470–484.
11.
DahlJ, OrmstadH, AassHC, MaltUF, BendzLT, SandvikL, BrundinL, AndreassenOA. 2014. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology, 45:77–86.
12.
DeslauriersJ, van WijngaardeM, GeyerMA, PowellS, RisbroughVB. 2017. Effects of LPS-induced immune activation prior to trauma exposure on PTSD-like symptoms in mice. Behav Brain Res, 323:117–123.
13.
DuguéB, LeppänenE, GräsbeckR. 1996. Preanalytical factors and the measurement of cytokines in human subjects. Int J Clin Lab Res, 26(2):99–105.
14.
EckartC, StoppelC, KaufmannJ, TempelmannC, HinrichsH, ElbertT, HeinzeHJ, KolassaIT. 2011. Structural alterations in lateral prefrontal, parietal and posterior midline regions of men with chronic posttraumatic stress disorder. J Psychiatry Neurosci, 36(3):176–186.
15.
ElhaiJD, FranklinCL, GrayMJ. 2008. The SCID PTSD module's trauma screen: validity with two samples in detecting trauma history. Depress Anxiety, 25(9):737–741.
16.
FoaEB, CashmanL, JaycoxL, PerryK. 1997. The validation of a self-report measure of posttraumatic stress disorder: the Posttraumatic Diagnostic Scale. Psychol Assess, 9(4):445–451.
GillJ, VythilingamM, PageGG. 2008. Low cortisol, high DHEA, and high levels of stimulated TNF-alpha, and IL-6 in women with PTSD. J Trauma Stress, 21(6):530–539.
19.
GolaH, EnglerH, SommershofA, AdenauerH, KolassaS, SchedlowskiM, GroettrupM, ElbertT, KolassaIT. 2013. Posttraumatic stress disorder is associated with an enhanced spontaneous production of pro-inflammatory cytokines by peripheral blood mononuclear cells. BMC Psychiatry, 13:40.
20.
GoswamiS, Rodriguez-SierraO, CascardiM, PareD. 2013. Animal models of post-traumatic stress disorder: face validity. Front Neurosci, 7:89.
21.
GreavesMW. 1976. Anti-inflammatory action of corticosteroids. Postgrad Med J, 52(612):631–633.
22.
GriffinMG, UhlmansiekMH, ResickPA, MechanicMB. 2004. Comparison of the posttraumatic stress disorder scale versus the clinician-administered posttraumatic stress disorder scale in domestic violence survivors. J Trauma Stress, 17(6):497–503.
23.
HogeEA, BrandstetterK, MoshierS, PollackMH, WongKK, SimonNM. 2009. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety, 26(5):447–455.
24.
JergovićM, BendeljaK, Savic MlakarA, VojvodaV, AberleN, JovanovicT, RabaticS, SabioncelloA, VidovicA. 2015. Circulating levels of hormones, lipids, and immune mediators in post-traumatic stress disorder—a 3-month follow-up study. Front Psychiatry, 6:49.
25.
JonesME, LebonvilleCL, BarrusD, LysleDT. 2015. The role of brain interleukin-1 in stress-enhanced fear learning. Neuropsychopharmacology, 40(5):1289–1296.
26.
KeaneTM, MarxBP, SloanDM. 2009. Post-traumatic stress disorder: definition, prevalence and risk factors. In: ShiromaniPJ, KeaneTM, LeDouxJE, eds. Post-traumatic Stress Disorder. New York: Humana Press. pp. 1–22.
27.
KimYK, WonE. 2017. The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder. Behav Brain Res, 329:6–11.
28.
KingLA, KingDW, LeskinG, FoyDW. 1995. The Los Angeles symptom checklist: a self report measure of posttraumatic stress disorder. Assessment, 2(1):1–17.
29.
KitayamaN, VaccarinoV, KutnerM, WeissP, BremnerJD. 2005. Magnetic resonance imaging (MRI) measurement of hippocampal volume in posttraumatic stress disorder: a meta-analysis. J Affect Disord, 88(1):79–86.
30.
LazukoSS, KuzhelOP, BelyaevaLE, ManukhinaEB, Fred DowneyH, TseilikmanOB, KomelkovaMV, TseilikmanVE. 2017. Posttraumatic stress disorder disturbs coronary tone and its regulatory mechanisms. Cell Mol Neurobiol. DOI:10.1007/s10571-017-0517-x.
31.
LeeB, SurB, YeomM, ShimI, LeeH, HahmDH. 2016. Effects of systemic administration of ibuprofen on stress response in a rat model of post-traumatic stress disorder. Korean J Physiol Pharmacol, 20(4):357–366.
32.
LindqvistD, WolkowitzOM, MellonS, YehudaR, FloryJD, Henn-HaaseC, BiererLM, Abu-AmaraD, CoyM, NeylanTC, MakotkineI, ReusVI, YanX, TaylorNM, MarmarCR, DhabharFS. 2014. Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. Brain Behav Immun, 42:81–88.
33.
LiuFF, YangLD, SunXR, ZhangH, PanW, WangXM, YangJJ, JiMH, YuanHM. 2016. NOX2 mediated-parvalbumin interneuron loss might contribute to anxiety-like and enhanced fear learning behavior in a rat model of post-traumatic stress disorder. Mol Neurobiol, 53(10):6680–6689.
34.
LiuYL, BiH, FanR, LiYH, WangYM, ChenYM, ChenJY, ChiSM, PeiJM. 2012. Effect of compound nutrients on acute immobilization and cold water-immersion stress-induced changes of Th1/Th2 cytokines. Chin J Cell Mol Immunol, 28(6):601–603.
35.
LobbestaelJ, LeurgansM, ArntzA. 2011. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II). Clin Psychol Psychother, 18(1):75–79.
36.
Lopez-CastejonG, BroughD. 2011. Understanding the mechanism of IL-1beta secretion. Cytokine Growth Factor Rev, 22(4):189–195.
37.
MichopoulosV, NorrholmSD, JovanovicT. 2015. Diagnostic biomarkers for posttraumatic stress disorder: promising Horizons from translational neuroscience research. Biol Psychiatry, 78(5):344–353.
38.
MinamiM, KuraishiY, YamaguchiT, NakaiS, HiraiY, SatohM. 1991. Immobilization stress induces interleukin-1 beta mRNA in the rat hypothalamus. Neurosci Lett, 123(2):254–256.
39.
MoherD, LiberatiA, TetzlaffJ, AltmanD, GroupP. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(7):e1000097.
40.
MoreyRA, GoldAL, LaBarKS, BeallSK, BrownVM, HaswellCC, NasserJD, WagnerHR, McCarthyG, Mid-Atlantic MIRECC Workgroup. 2012. Amygdala volume changes in posttraumatic stress disorder in a large case-controlled veterans group. Arch Gen Psychiatry, 69(11):1169–1178.
41.
NguyenKT, DeakT, OwensSM, KohnoT, FleshnerM, WatkinsLR, MaierSF. 1998. Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci, 18(6):2239–2246.
42.
O'DohertyDC, ChittyKM, SaddiquiS, BennettMR, LagopoulosJ. 2015. A systematic review and meta-analysis of magnetic resonance imaging measurement of structural volumes in posttraumatic stress disorder. Psychiatry Res, 232(1):1–33.
43.
OganesyanLP, MkrtchyanGM, SukiasyanSH, BoyajyanAS. 2009. Classic and alternative complement cascades in post-traumatic stress disorder. Bull Exp Biol Med, 148(6):859–861.
44.
PassosIC, Vasconcelos-MorenoMP, CostaLG, KunzM, BrietzkeE, QuevedoJ, SalumG, MagalhaesPV, KapczinskiF, Kauer-Sant'AnnaM. 2015. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry, 2(11):1002–1012.
45.
PattersonSL. 2015. Immune dysregulation and cognitive vulnerability in the aging brain: interactions of microglia, IL-1β, BDNF and synaptic plasticity. Neuropharmacology, 96:11–18.
46.
PengZ, WangH, ZhangR, ChenY, XueF, NieH, ChenY, WuD, WangY, WangH, TanQ. 2013. Gastrodin ameliorates anxiety-like behaviors and inhibits IL-1beta level and p38 MAPK phosphorylation of hippocampus in the rat model of posttraumatic stress disorder. Physiol Res, 62(5):537–545.
47.
PughCR, NguyenKT, GonyeaJL, FleshnerM, WakinsLR, MaierSF, RudyJW. 1999. Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation. Behav Brain Res, 106(1–2):109–118.
48.
QuanN. 2008. Immune-to-brain signaling: how important are the blood-brain barrier-independent pathways?. Mol Neurobiol, 37(2–3):142–152.
49.
RauV, DeColaJP, FanselowMS. 2005. Stress-induced enhancement of fear learning: an animal model of posttraumatic stress disorder. Neurosci Biobehav Rev, 29(8):1207–1223.
50.
SheeranT, ZimmermanM. 2002. Screening for posttraumatic stress disorder in a general psychiatric outpatient setting. J Consult Clin Psychol, 70(4):961.
51.
ShinLM, RauchSL, PitmanRK. 2006. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann N Y Acad Sci, 1071:67–79.
TuckerP, RuweWD, MastersB, ParkerDE, HossainA, TrautmanRP, WyattDB. 2004. Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol Psychiatry, 56(2):121–128.
54.
von KänelR, HeppU, KraemerB, TraberR, KeelM, MicaL, SchnyderU. 2007. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res, 41(9):744–752.
55.
WangZ, YoungMR. 2016. PTSD, a disorder with an immunological component. Front Immunol, 7:219.
56.
WeathersFW, LitzBT, KeaneTM, PalmieriPA, MarxBP, SchnurrPP. 2013. The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD. Available at www.ptsd.va.gov (accessed July12, 2017).
57.
WilsonB, McLaughlinL, NairAR, DangeR, FrancisJ. 2013. Inflammation, oxidative stress, and neuroprotective factors in the pathophysiology of PTSD in an animal model. FASEB J, 27:691.5.
58.
WoonFL, HedgesDW. 2009. Amygdala volume in adults with posttraumatic stress disorder: a meta-analysis. J Neuropsychiatry Clin Neurosci, 21(1):5–12.
59.
World Health Organization. 1992. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization.
60.
YamamotoS, MorinobuS, TakeiS, FuchikamiM, MatsukiA, YamawakiS, LiberzonI. 2009. Single prolonged stress: toward an animal model of posttraumatic stress disorder. Depress Anxiety, 26(12):1110–1117.
61.
YangR, WangQ, MinL, SuiR, LiJ, LiuX. 2013. Monosialoanglioside improves memory deficits and relieves oxidative stress in the hippocampus of rat model of Alzheimer's disease. Neurol Sci, 34(8):1447–1451.
62.
ZandiehS, BerntR, KnollP, WenzelT, HittmairK, HallerJ, HerganK, MirzaeiS. 2016. Analysis of the metabolic and structural brain changes in patients with torture-related post-traumatic stress disorder (TR-PTSD) using (1)(8)F-FDG PET and MRI. Medicine, 95(15):e3387.
63.
ZhouJ, NagarkattiP, ZhongY, GinsbergJP, SinghNP, ZhangJ, NagarkattiM. 2014. Dysregulation in microRNA expression is associated with alterations in immune functions in combat veterans with post-traumatic stress disorder. PLoS One, 9(4):e94075.
64.
ZimmermanG, ShaltielG, BarbashS, CohenJ, GashoCJ, Shenhar-TsarfatyS, ShalevH, BerlinerSA, ShelefI, ShohamS, FriedmanA, CohenH, SoreqH. 2012. Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFkappaB pathway. Transl Psychiatry, 2:e78.
